WallStSmart

Clover Health Investments Corp (CLOV)vsCVS Health Corp (CVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CVS Health Corp generates 18251% more annual revenue ($405.62B vs $2.21B). CVS leads profitability with a 0.7% profit margin vs -2.6%. CVS earns a higher WallStSmart Score of 65/100 (C+).

CLOV

Hold

35

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 6.7Quality: 3.8
Piotroski: 2/9Altman Z: -1.87

CVS

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 4.0Value: 8.0Quality: 5.0
Piotroski: 4/9Altman Z: 2.11
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CLOVUndervalued (+69.5%)

Margin of Safety

+69.5%

Fair Value

$6.72

Current Price

$3.83

$2.89 discount

UndervaluedFair: $6.72Overvalued
CVSUndervalued (+45.4%)

Margin of Safety

+45.4%

Fair Value

$141.01

Current Price

$95.93

$45.08 discount

UndervaluedFair: $141.01Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CLOV1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
62.0%10/10

Revenue surging 62.0% year-over-year

CVS5 strengths · Avg: 9.0/10
PEG RatioValuation
0.2610/10

Growing faster than its price suggests

EPS GrowthGrowth
63.1%10/10

Earnings expanding 63.1% YoY

Market CapQuality
$114.20B9/10

Large-cap with strong market position

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$3.40B8/10

Generating 3.4B in free cash flow

Areas to Watch

CLOV4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
3.6%3/10

Operating margin of 3.6%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-16.8%2/10

ROE of -16.8% — below average capital efficiency

CVS4 concerns · Avg: 3.3/10
P/E RatioValuation
39.3x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
3.8%3/10

ROE of 3.8% — below average capital efficiency

Profit MarginProfitability
0.7%3/10

0.7% margin — thin

Operating MarginProfitability
4.1%3/10

Operating margin of 4.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : CLOV

The strongest argument for CLOV centers on Revenue Growth. Revenue growth of 62.0% demonstrates continued momentum.

Bull Case : CVS

The strongest argument for CVS centers on PEG Ratio, EPS Growth, Market Cap. PEG of 0.26 suggests the stock is reasonably priced for its growth.

Bear Case : CLOV

The primary concerns for CLOV are EPS Growth, Operating Margin, Piotroski F-Score.

Bear Case : CVS

The primary concerns for CVS are P/E Ratio, Return on Equity, Profit Margin. Thin 0.7% margins leave little buffer for downturns.

Key Dynamics to Monitor

CLOV profiles as a hypergrowth stock while CVS is a value play — different risk/reward profiles.

CLOV carries more volatility with a beta of 2.48 — expect wider price swings.

CLOV is growing revenue faster at 62.0% — sustainability is the question.

CVS generates stronger free cash flow (3.4B), providing more financial flexibility.

Bottom Line

CVS scores higher overall (65/100 vs 35/100). CLOV offers better value entry with a 69.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Clover Health Investments Corp

HEALTHCARE · HEALTHCARE PLANS · USA

Clover Health Investments, Corp. The company is headquartered in Franklin, Tennessee.

Visit Website →

CVS Health Corp

HEALTHCARE · HEALTHCARE PLANS · USA

CVS Health (previously CVS Corporation and CVS Caremark Corporation) is an American healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands. The company's headquarters is in Woonsocket, Rhode Island.

Visit Website →

Want to dig deeper into these stocks?